November 6, 2022Open Access
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Key Points
Key points are not available for this paper at this time.
Abstract
Olpasiran therapy significantly reduced lipoprotein(a) concentrations in patients with established atherosclerotic cardiovascular disease. Longer and larger trials will be necessary to determine the effect of olpasiran therapy on cardiovascular disease. (Funded by Amgen; OCEANa-DOSE ClinicalTrials.gov number, NCT04270760.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
M
Michelle L. O’Donoghue
General Cardiology
Robert S. Rosenson
Preventive Cardiology
B
Bariş Gencer
Preventive Cardiology
Journals
New England Journal of Medicine
Actions
Institutions
University of California, Los Angeles
Brigham and Women's Hospital
Université de Montréal
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...